A drug therapy for muscle dysfunction in respiratory disorders?

American Journal of Respiratory and Critical Care Medicine

Volumn 185, Issue 1, 2012, Pages 10-11

  Gea, Joaquim ^a  

^a INST MUNIC D INVESTIGACIO MEDICA   (Spain)

Author keywords

[No Author keywords available]

Indexed keywords

AMINOPHYLLINE; DOPAMINE; LEVOSIMENDAN;

ASTHMA; BREATHING MUSCLE; CHRONIC OBSTRUCTIVE LUNG DISEASE; CONGESTIVE HEART FAILURE; CRITICALLY ILL PATIENT; CYSTIC FIBROSIS; EDITORIAL; HEART FAILURE; HUMAN; LUNG VENTILATION PERFUSION RATIO; MUSCLE DISEASE; MUSCLE FATIGUE; MUSCLE WEAKNESS; PHYSICAL ACTIVITY; PRIORITY JOURNAL; PULMONARY REHABILITATION; RESPIRATORY TRACT DISEASE; SMOKING CESSATION; VASODILATATION;

DIAPHRAGM; FEMALE; HUMANS; HYDRAZONES; MALE; MUSCLE CONTRACTION; MUSCLE WEAKNESS; PHOSPHODIESTERASE INHIBITORS; PYRIDAZINES;

EID: 84855293904     PISSN: 1073449X     EISSN: 15354970     Source Type: Journal    
DOI: 10.1164/rccm.201110-1858ED     Document Type: Editorial

References (19)

1. Doorduin J, Sinderby CA, Beck J, Stegeman DF, van Hees HW, van der Hoeven JG, Heunks LM. The calcium sensitizer levosimendan improves human diaphragm function. Am J Respir Crit Care Med. 2012;185:90-95.
2. American Thoracic Society. Skeletal muscle dysfunction in chronic obstructive pulmonary disease: a statement of the American Thoracic Society and European Respiratory Society. Am J Respir Crit Care Med 1999;159:S1-S40.
3. Orozco-Levi M, Lloreta J, Minguella J, Serrano S, Broquetas J, Gea J. Injury of the human diaphragm associated with exertion and COPD. Am J Respir Crit Care Med 2001;164:1734-1739.
4. Sanchez J, Medrano G, Debesse B, Riquet M, Derenne JP. Muscle fibre types in costal and crural diaphragm in normal men and in patients with moderate chronic respiratory disease. Bull Eur Physiopathol Respir 1985;21:351-356. (Pubitemid 15001309)
5. Levine S, Nguyen T, Taylor N, Friscia ME, Budak MT, Rothenberg P, Zhu J, Sachdeva R, Sonnad S, Kaiser LR, et al. Rapid disuse atrophy of diaphragm fibers in mechanically ventilated humans. N Engl J Med 2008;358:1327-1335. (Pubitemid 351468409)
6. Stassijns G, Lysens R, Decramer M. Peripheral and respiratory muscles in chronic heart failure. Eur Respir J 1996;9:2161-2167. (Pubitemid 26333560)
7. Levine S, Kaiser L, Leferovich J, Tikunov B. Cellular adaptations in the diaphragm in chronic obstructive pulmonary disease. N Engl J Med1997;337:1799-1806. (Pubitemid 28006784)
8. Agustí AG, Sauleda J, Miralles C, Gomez C, Togores B, Sala E, Batle S, Busquets X. Skeletal muscle apoptosis and weight loss in chronic obstructive pulmonary disease. Am J Respir Crit Care Med 2002;166: 485-489.
9. Debigaré R, Côte CH, Hould FS, LeBlanc P, Maltais F. In vitro and in vivo contractile properties of the vastus lateralis muscle in males withCOPD. Eur Respir J 2003;21:273-278. (Pubitemid 36204542)
10. Ottenheijm CA, Heunks LM, Li YP, Jin B, Minnaard R, van Hees HW, Dekhuijzen PN. Activation of the ubiquitin-proteasome pathway in the diaphragm in chronic obstructive pulmonary disease. Am J Respir Crit Care Med 2006;174:997-1002. (Pubitemid 44684448)
11. Barreiro E, Gea J, Corominas JM, Hussain SN. Nitric oxide synthases and protein oxidation in the quadriceps femoris of patients with chronic obstructive pulmonary disease. Am J Respir Cell Mol Biol 2003;29:771-778. (Pubitemid 38045945)
12. Rutten EP, Franssen FM, Engelen MP, Wouters EF, Deutz NE, Schols AM. Greater whole-body myofibrillar protein breakdown in cachectic patients with chronic obstructive pulmonary disease. Am J Clin Nutr 2006;83:829-834. (Pubitemid 44713147)
13. Van Hees HW, Dekhuijzen PN, Heunks LM. Levosimendan enhances force generation of diaphragm muscle from patients with chronic obstructive pulmonary disease. Am J Respir Crit Care Med 2009;179:41-47.
14. Ochala J, Radell PJ, Eriksson LI, Larsson L. EMD 57033 partially reverses ventilator-induced diaphragm muscle fiber calcium desensitization. Pflugers Arch 2010;459:475-483.
15. Van Hees HW, van der Heijden HF, Ottenheijm CA, Heunks LM, Pigmans CJ, Verheugt FW, Brouwer RM, Dekhuijzen PN. Diaphragm single-fiber weakness and loss of myosin in congestive heart failure rats. Am J Physiol Heart Circ Physiol 2007;293:H819-H828. (Pubitemid 47105147)
16. Sorsa T, Pollesello P, Solaro RJ. The contractile apparatus as a target for drugs against heart failure: interaction of levosimendan, a calcium sensitizer, with cardiac troponin c. Mol Cell Biochem 2004;266:87-107. (Pubitemid 39562310)
17. Antila S, Sundberg S, Lehtonen LA. Clinical pharmacology of levosimendan. Clin Pharmacokinet 2007;46:535-552. (Pubitemid 47025356)
18. Nieminen MS, Cleland JG, Eha J, Belenkov Y, Kivikko M, Pöder P, Sarapohja T. Oral levosimendan in patients with severe chronic heart failure: the PERSIST study. Eur J Heart Fail 2008;10:1246-1254.
19. Ochala J. Ca2+ sensitizers: an emerging class of agents for counter-balancing weakness in skeletal muscle diseases? Neuromuscul Disord 2010;20:98-101.